Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference
March 18, 2019 08:30 ET
|
Dare Bioscience, Inc.
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive...
Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA
March 18, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of clinical findings for...
Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®
March 11, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received a second Notice of Award of $982,851, part...
Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference
March 05, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive...
Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference
February 28, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer,...
Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference
February 05, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer,...
Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
January 02, 2019 08:00 ET
|
Dare Bioscience, Inc.
Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trialInitiation of at-home portion of Sildenafil Cream, 3.6% Phase 2b Initiation of pivotal Phase 3 study of...
Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis
December 06, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive...
Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
November 29, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, and Strategic Science & Technologies, LLC (SST), a...
Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
November 27, 2018 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling patients in an...